Biogen

Biogen’s pricing power is anchored in exclusivity windows and specialty positioning rather than structural monopolies.

Leqembi’s U.S. list price was set at 26,500 dollars per year for IV dosing; the subcutaneous maintenance autoinjector is listed lower at about 19,500 dollars annually, reflecting a convenience format aimed at adoption rather than extraction of price.

IRA negotiation constraints are limited near term for new biologics, but payer management, monitoring costs (MRIs), and competitor reference pricing with Kisunla cap latent pricing expansion.

Rare disease assets (Skyclarys, Qalsody) usually carry stronger pricing power per patient, yet very small populations and access programs temper aggregate leverage. Net effect: reasonable pricing power in pockets, but constrained by competition, payers and safety requirements.

We see room for mix-driven margin improvement from format shifts and manufacturing efficiency rather than headline price hikes.